Interception of complex chronic conditions during asymptomatic stages drastically improves clinical prognosis. Advances in high-throughput proteomic profiling and multi-cancer early detection (MCED) liquid biopsies are transforming clinical screening protocols.
Cell-Free DNA (cfDNA) Methylation & Fragmentation Profiling
Tumor cells shed cell-free DNA into the peripheral bloodstream. Unlike conventional single-biomarker assays (e.g., PSA, CA-125), multi-cancer liquid biopsies utilize deep targeted bisulfite sequencing and machine learning to analyze genome-wide DNA methylation patterns:
- Cancer Signal Origin (CSO): Epigenetic tissue-of-origin signatures accurately identify the anatomical location of malignancies with >85% precision.
- Fragmentomics: Aberrant cfDNA fragmentation lengths reflect chromatin organization unique to cancerous cells.
SomaScan & Olink Proximity Extension Assays (PEA)
Modern proteomic platforms measure over 5,000 plasma proteins simultaneously from a single blood draw, detecting early inflammatory cascades, subclinical cardiovascular microvascular damage, and neurodegenerative amyloid precursors years before symptom onset.